AbbVie's Parkinson's disease drug meets main goal in late-stage trial

AbbVie's (ABBV.N) drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.
Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale.